Get started
Author

Aaron Holmes

Observed name: Aaron N. Holmes
ORCID: 0000-0001-8470-773X
Observed ORCID: 0000-0001-8470-773X
OpenAlex ID: A5086800953
Immune thrombocytopenia in patients treated with immune checkpoint inhibitors
2025 · Rebecca K. Leaf, Jodi V. Mones, et al. · Blood · 13
Supplementary Figure S2 from A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti–PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer
2026 · Scott T. Tagawa, Charlene Thomas, et al.
Supplementary Methods S1 from A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti–PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer
2026 · Scott T. Tagawa, Charlene Thomas, et al.
Supplementary Table S7 from A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti–PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer
2026 · Scott T. Tagawa, Charlene Thomas, et al.
Data from A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti–PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer
2026 · Scott T. Tagawa, Charlene Thomas, et al.
Supplementary Figure S4 from A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti–PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer
2026 · Scott T. Tagawa, Charlene Thomas, et al.
Supplementary Table S4 from A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti–PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer
2026 · Scott T. Tagawa, Charlene Thomas, et al.
Supplementary Table S2 from A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti–PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer
2026 · Scott T. Tagawa, Charlene Thomas, et al.
Supplementary Table S1 from A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti–PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer
2026 · Scott T. Tagawa, Charlene Thomas, et al.
Supplementary Table S6 from A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti–PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer
2026 · Scott T. Tagawa, Charlene Thomas, et al.
Supplementary Table S3 from A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti–PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer
2026 · Scott T. Tagawa, Charlene Thomas, et al.
Supplementary Figure S1 from A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti–PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer
2026 · Scott T. Tagawa, Charlene Thomas, et al.
Supplementary Table S5 from A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti–PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer
2026 · Scott T. Tagawa, Charlene Thomas, et al.
Supplementary Figure S3 from A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti–PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer
2026 · Scott T. Tagawa, Charlene Thomas, et al.
A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti–PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer
2026 · Scott T. Tagawa, Charlene Thomas, et al. · Clinical Cancer Research
Site-Directed Spin-Label EPR Spectroscopy of Influenza a M2 Protein
2018 · Aaron Holmes, Kathleen Howard · Biophysical Journal
PDF
Works count: 16
Citation count: 13
H-index: 1
I10-index: 1
Year
Topic
Type